adlitterio66339

About adlitterio66339

This author has not yet filled in any details.
So far adlitterio66339 has created 727 blog entries.

2 08, 2024

Elena Orlandi et al., Evolving approaches in advanced gallbladder cancer with complete pathological response using chemo?immunotherapy: A case report

adlitterio663392024-10-07T11:14:02+02:00

26 07, 2024

Arsenal Sezgin Alikanoglu et al., Detection of High-Risk Human Papillomavirus (HPV), p16 and EGFR in Lung Cancer: Insights from the Mediterranean Region of Turkey

adlitterio663392024-07-26T11:01:07+02:00

11 07, 2024

Shooting Cancer Highlights – Periodic Focus on regulatory status of new targeted therapies in oncology

adlitterio663392024-07-11T14:10:47+02:00

10 07, 2024

Anna Caliò et al., Comparison of Primary and Metastatic Fumarate Hydratase-Deficient Renal Cell Carcinomas Documents Morphologic Divergence and Potential Diagnostic Pitfall With Peritoneal Mesothelioma

adlitterio663392024-07-10T10:29:34+02:00

15 05, 2024

Professor Giovanni Scambia joins Diatech Pharmacogenetics‘ Scientific Board
Professor Giovanni Scambia joins Diatech Pharmacogenetics‘ Scientific Board

Nachrichten

Professor Giovanni Scambia joins Diatech Pharmacogenetics‘ Scientific Board

adlitterio663392024-05-15T16:44:23+02:00

14 05, 2024

Shooting Cancer Highlights – Focus periodico su approvazioni e disponibilità di nuove terapie oncologiche a bersaglio molecolare

adlitterio663392024-05-14T14:49:14+02:00

11 05, 2024

Martina Verrienti et al., Somatic RAS mutations in thyroid nodules: possible protective effect?

adlitterio663392024-05-11T10:23:09+02:00

6 05, 2024

Zahra Mosaferi et al., Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients

adlitterio663392024-05-06T10:14:05+02:00

6 05, 2024

Andrea Sbrana et al., Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience

adlitterio663392024-05-06T10:08:49+02:00

30 04, 2024

Carolin Schmidt et al., Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Tissue

adlitterio663392024-04-30T09:32:50+02:00

Vorheriges 456 Nächstes